Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders
10.10.2024 16:17:00 CEST | Business Wire | Press release
Offering empowers OEM's and ISV’s to develop products up to 3X faster and reduce costs of ownership by 80%
Cognite,the Data and AI authority for industry, today announced the launch of Cognite Embedded. This new offering enables Original Equipment Manufacturers (OEMs) and Industrial Software Vendors (ISVs) to accelerate time to market, drastically reduce total cost of ownership, and future-proof their digital solutions with AI-ready architectures, all through Cognite’s leading industrial data platform, Cognite Data Fusion, and low-code industrial agent workbench, Cognite Atlas AI ®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009752580/en/

Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders (Photo: Business Wire)
Integrating and contextualizing data is often the biggest hurdle for OEMs and ISVs. Additionally, they need to onboard new customers and roll out data-driven solutions without the high costs associated with maintaining complex custom infrastructures.
Cognite Embedded empowers OEMs and ISVs to accelerate product development by 2-3x and reduce their total cost of ownership by up to 80% by leveraging Cognite Data Fusion’s powerful industrial data modeling features, unique contextualization capabilities that address both structured and unstructured industrial data, and built-in scalability.
Cognite Atlas AI makes it easier to integrate Industrial AI agents into products and solutions for industrial use cases like predictive maintenance and real-time operational optimization, allowing OEMs and ISVs to future-proof their architectures and end-user interfaces.
"By building on Cognite Data Fusion, we've been able to bring our solutions to market at lightning speed," said Arvind Rao, VP Industry Solutions, Data & Analytics, Rockwell Automation. “Partnering with Cognite to develop our FactoryTalk DataMosaix platform has streamlined our development process, allowing us to focus on delivering value to our customers while cutting our time to market significantly. We’re now delivering advanced digital solutions like Energy Management, leveraging Cognite Data Fusion, faster than ever before."
"Cognite's platform has enabled us to seamlessly integrate our offering for reliability- Newton into our customers' systems," said Mark Felder, CTO of Pinnacle Reliability. "Cognite Data Fusion has empowered our services teams to quickly deploy new tools, reports, and data analytics, allowing them to focus on delivery and integration independently from our development teams, which enables us to concentrate on new innovations and bring value to our customers more quickly."
"Partnering with Cognite has empowered us to unlock and utilize data from production operations, fundamentally transforming how we fuel AI and deliver value to our customers through our Lumi platform," said Shashi Menon, VP of Digital Development at SLB. "The scalability and adaptability of Cognite Data Fusion equips us to help our customers harness their production data, optimizing operations through our OptiSite and OptiFlow solutions.”
“The launch of Cognite Embeddedis a testament to Cognite’s commitment to enabling OEMs and ISVs to build and scale the next generation of industrial solutions,” said Girish Rishi, CEO, Cognite. "With Cognite Embedded, equipment and software builders and developers can focus on delivering cutting-edge products without the typical data complexities that slow down innovation. Our platform offers speed, scalability, and the flexibility to integrate AI in a way that future-proofs their solutions for years to come."
The Cognite Embedded offering includes the Embedded Team, a dedicated partner service that will help OEMs and ISVs leverage industrial data for greater efficiency, smarter decision-making, and sustained innovation.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009752580/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom